Skip to main content

Mintz Life Sciences Deal Activity (October – December 2020)

Mergers & Acquisitions

  • Represented Neurotrope, Inc. in its reverse merger with Metuchen Pharmaceuticals, LLC to form Petros Pharmaceuticals (December 2020)
    • Simultaneously represented Neurotrope in the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain cash retained in accordance with the terms of the Merger Agreement, into a separately traded public company
  • Represented F-Star Therapeutics in its reverse merger with Spring Bank Pharmaceuticals (November 2020)
  • Represented Athenen Therapeutics in its merger with Eliem Therapeutics (October 2020)

Venture Capital

  • Represented Matrix Capital Management in its $15M investment in AltPep Corporation (December 2020)
  • Represented Antharis Therapeutics, Inc. in its $5.2M Series Seed financing led by Bionext Ltd. (December 2020)
  • Represented DxLab Inc. in its $4M Series Seed Preferred Stock financing led by Neoteny and E14 (December 2020)
  • Represented Avilar Therapeutics, Inc. in its $60M Series Seed financing (December 2020)
  • Represented Hopewell Therapeutics in its $500K Convertible Note financing (December 2020)
  • Represented NanoView Biosciences in its $6M extension of its Series B financing from a mix of existing and new investors (December 2020)
  • Represented PanTher Therapeutics, Inc. in its $1M extension of its Series A financing led by Angel Physicians Fund, LLC and Sayan Bioventure IV, LLC (November 2020)
  • Represented Endotronix, Inc. in its $15M extension of its Series D financing, bringing the total for the round to $70M (November 2020)
  • Represented DoubleRainbow Biosciences in its $30M Series B financing led by Gaorong Capital (October 2020)

Capital Markets

Represented the issuer:

  • Represented ImmunoGen, Inc. in its $150M at-the-market offering with Jefferies LLC acting as sales agent (December 2020)
  • Represented SELLAS Life Sciences Group, Inc. in its $16.2M registered direct offering with Maxim Group LLC acting as the placement agent (December 2020)
  • Represented Cyclacel Pharmaceuticals, Inc. in its $7M registered direct offering and concurrent private placement (December 2020)
  • Represented Fulgent Genetics in its $175M at-the-market offering with Piper Sandler & Co., BTIG, LLC and Oppenheimer & Co. Inc. acting as sales agents (November 2020)
  • Represented DermTech, Inc. in its $50M at-the-market offering with Cowen and Company LLC acting as sales agent (November 2020)
  • Represented Evofem Biosciences, Inc. in its $25M Convertible Note transaction with Adjuvant Capital (October 2020)

Represented the underwriters:

  • Represented the underwriters in the $147M public offering of Curis, Inc. underwritten by H.C. Wainwright & Co., LLC, Laidlaw & Company (UK) Ltd., Cantor Fitzgerald & Co. and JonesTrading Institutional Services, LLC (December 2020)
  • Represented the underwriters in the $3.2M Regulation A initial public offering of Scopus BioPharma Inc. underwritten by The Benchmark Company, LLC and Joseph Gunnar & Co., LLC (December 2020)
  • Represented the underwriters in the $80M initial public offering of Galecto, Inc. underwritten by BofA Securities, SVB Leerink, Credit Suisse and Kempen & Co. (November 2020)
  • Represented the underwriters in the $40M public offering of Forte Biosciences, Inc. underwritten by Truist Securities, Inc., Ladenburg Thalmann & Co. Inc., Chardan Capital Markets, LLC and Brookline Capital Markets, LLC (October 2020)
  • Represented the underwriters in the $9.5M public offering of Isoray, Inc. underwritten by Oppenheimer & Co. Inc. (October 2020)
  • Represented the underwriters in the $190M initial public offering of Praxis Precision Medicines, Inc. underwritten by Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets (October 2020)
  • Represented the underwriters in the $6.6M public offering of Artelo Biosciences, Inc. underwritten by Ladenburg Thalmann & Co. Inc. (October 2020)

Represented the sales agent / placement agent:

  • Represented the sales agent in a $50M at-the-market offering of Rezolute, Inc. with Oppenheimer & Co. Inc. acting as sales agent (December 2020)
  • Represented the sales agents in a $25M at-the-market offering of VolitionRx Limited with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. acting as sales agents (November 2020)

View Deal Activity from July - September 2020

View Deal Activity from April – June 2020

Subscribe To Viewpoints